Introduction {#sec1-1}
============

Avian pathogenic *Escherichia coli* (APEC) is a subgroup of extraintestinal pathogenic *E. coli*, enters through different routes including genital and respiratory tracts and causes various extraintestinal diseases collectively known as collibacillosis in chickens, which are responsible for high economic losses in the chicken industry \[[@ref1]\]. The pathogenicity of APEC allows certain intestinal commensal *E. coli* to become APEC \[[@ref2]\]. APEC belongs mostly to the serotypes O1, O2, and O78 or is often nontypable. APEC is also suspected to be a potential zoonotic risk for human \[[@ref3]\].

Treatment of diseases caused by *E. coli* usually necessitates antimicrobial chemotherapy. The decision of using antimicrobial therapy based on the microorganism susceptibility and the drug pharmacokinetics for obtaining the required therapeutic concentration at the site of infection and therefore clinical efficacy \[[@ref4]\]. Therefore, veterinarians have a restricted choice of antimicrobial agents to use it in the poultry industry, due to problems of multidrug-resistance (MDR) and human health hazard. Moreover, the constant misuse of antimicrobials led to increase rate of antibiotic resistance \[[@ref5]\]. Antibiotic resistance is a major problem that threatens human and animal health especially in underdeveloped and developing countries where antibiotics are used without control for prophylaxis and treatment of human and animal illnesses \[[@ref6]\]. *E. coli* present in both human and animals possess resistance to several classes of antibiotics such as aminoglycosides, penicillin, streptomycin, cephalosporins, sulfonamides, tetracycline, and quinolones \[[@ref7]\].

Many drug-resistant strains and genes can be transmitted and disseminated between animal and human pathogens, which not only increases the difficulty in treating animal diseases but also threatens the human health \[[@ref8]\]. Therefore, the main goal of this study was to, determine the antibiotic resistance profile of APEC isolates and to detect their associated antibiotic resistance genes.

Materials and Methods {#sec1-2}
=====================

Ethical approval {#sec2-1}
----------------

There is no ethical approval necessary.

Samples collection {#sec2-2}
------------------

In this study, a total of 200 chicken visceral organs (liver, lungs, heart, spleen) and intestinal contents were collected randomly from diseased and freshly dead chicken broilers from different poultry farms located in the district of Mansoura City, Egypt. The chickens were ranged from 35 to 50 days old and showed different forms of diarrhea. The predominant lesions revealed in postmortem examination were ascites, pericarditis, splenitis, perihepatitis, airsacculitis, and peritonitis. Using sterile scissors and tissue forceps, the visceral organs from each bird were collected separately and put in a polyethylene bag and transferred immediately in an ice tank to the laboratory for bacteriological analysis.

Bacteriological examination {#sec2-3}
---------------------------

From each chicken visceral organ, 2 g was directly inoculated in MacConkey broth and incubated for 18 h at 37°C. Then, a loopful from the previously inoculated broth was streaked onto MacConkey agar (Oxoid) plates for 24 h at 37°C. Rose pink colonies were picked up and streaked onto Eosin Methylene Blue (Oxoid) and incubated overnight at 37°C. The identification of *E. coli* isolates depends on the colonies morphological characters, and biochemical tests results following Ewing \[[@ref9]\]. Further identification of *E. coli* isolates was done using commercial biochemical test kits (bioMerieux API, France).

Serotyping {#sec2-4}
----------

Serological identification of *E. coli* isolates was done using rapid diagnostic *E. coli* antisera sets (Denka Seiken Co., Japan) according to Kok *et al*. \[[@ref10]\] at the Department of Food Hygiene Control, University of Benha, Egypt.

Antimicrobial sensitivity testing {#sec2-5}
---------------------------------

It was performed by disc diffusion method using Muller-Hinton agar using 15 antibiotic disc belongs to seven different antimicrobial classes including sulfamethoxazole (100 µg/disk), levofloxacin (5 µg/disk), chloramphenicol (30 µg/disk), norfloxacine (10 µg/disk), tetracycline (30 µg/disk), streptomycin (10 µg/disk), cefoxitin (30 µg/disk), ampicillin/sulbactam (10 µg/disk), neomycin (30 µg/disk), doxycycline (30 µg/disk), cefepime (30 µg/disk), cefotaxime (30 µg/disk), penicillin (10 µg/disk), amoxicillin (10 µg/disk), and nalidixic acid (30 µg/disk). Interpretation of the results was done following Clinical and Laboratory Standards Institute Guidelines \[[@ref11]\].

DNA extraction {#sec2-6}
--------------

DNA was extracted according to Ramadan *et al*. \[[@ref12]\] briefly; three presumptive *E. coli* colonies were inoculated into 3 ml trypticase soy broth and incubated for 18 h at 37°C. 1 ml of the previously inoculated broth was centrifuged at 8,000 g for 2 min. The sediment was washed with DNase/RNase-free water and heated at 95°C for 15 min; the supernatants were used as DNA template.

Detecting antimicrobial resistance genes by multiplex PCR {#sec2-7}
---------------------------------------------------------

Multiplex PCR assay was done targeting five antibiotic resistance genes (bla~TEM~, bla~SHV~, TetA(A), *Aada2*, and *sul1*) of APEC isolates. Primers used for multiplex PCR are as per the previously reported researchers \[[@ref13]-[@ref16]\]. PCR was performed in a total volume of 50 µL consisting of 25 µL of 2X PCR Master Mix (Promega, Madison, USA), 1 µL of each primer (Metabion, Germany), and 6 µL DNA templates. After an initial denaturation at 94°C for 5 min, 35 amplification cycles consisting of denaturation at 94°C for 30 s, annealing at 54°C for 45 s, and extension at 72°C for 45 s per kbp were performed, followed by a final extension at 72°C for 10 min. Amplified genes were separated by electrophoresis in a 1.5% agarose gel. The separated PCR products were visualized under ultraviolet light and photographed.

Results {#sec1-3}
=======

Out of 200 examined specimens, *E. coli* was identified in 36.5% (73/200) of the total examined samples based on morphological and biochemical characteristics. The recovery rate of *E. coli* from different chicken samples was 28.76%, 27.39%, 23.28%, 15.06%, and 5.46% form lungs, spleen, heart, liver, and intestinal contents, respectively ([Table-1](#T1){ref-type="table"}). *E. coli* isolates were serotyped into 26 serotypes including O1, O2, O78, O26, O153, O114, O91, O121, O44, O63, O158, O171, O146, O124, O15, O8, O145, O117, O166, O128, O111, O55, O119, O159, O6, and O126 ([Table-2](#T2){ref-type="table"}). O78, O1, and O2 were the most prevalent serotypes with an incidence of 17.8%, 9.5%, and 9.5%, respectively.

###### 

Number of strains of avian pathogenic *E. coli* isolated from different samples.

  Organs                Number of isolated strains n=73 (%)
  --------------------- -------------------------------------
  Lungs                 21 (28.76)
  Liver                 11 (15.06)
  Spleen                20 (27.39)
  Intestinal contents   4 (5.47)
  Heart                 17 (23.28)

E. coli=Escherichia coli

###### 

Serogroups of avian pathogenic *E. coli.*

  Number of strains (n=73)   Type of samples                                               Serodiagnosis   Percentages
  -------------------------- ------------------------------------------------------------- --------------- -------------
  13                         Lungs (4), spleen (4), heart (3), intestinal content, liver   O78             17.8
  7                          Lungs (2), spleen (2), heart, liver, intestinal content       O2:H6           9.5
  7                          Lungs (2), heart (3), spleen (2)                              O1:H7           9.5
  4                          Heart (2), lungs, liver                                       O91:H21         5.4
  4                          Spleen, heart, lungs (2)                                      O8:H21          5.4
  3                          Spleen, lungs, liver                                          O114:H4         4
  3                          Lungs (2), heart                                              O126:H21        4
  3                          Heart, spleen, lungs                                          O26:H11         4
  3                          Spleen, liver, lungs                                          O145            4
  3                          Spleen, liver, heart                                          O44:H18         4
  2                          Intestinal contents, liver                                    O166            2.7
  2                          Lungs, heart                                                  O117:H7         2.7
  2                          Intestinal contents, lungs                                    O55:H7          2.7
  2                          Liver (2)                                                     O111:H2         2.7
  2                          Heart, spleen                                                 O124            2.7
  2                          Spleen, heart                                                 O158            2.7
  2                          Lungs, heart                                                  O128:H2         2.7
  1                          Lungs                                                         O153:H2         1.3
  1                          Liver                                                         O119:H6         1.3
  1                          Spleen                                                        O63             1.3
  1                          Spleen                                                        O15:H2          1.3
  1                          Lungs                                                         O159:H21        1.3
  1                          Spleen                                                        O171:H2         1.3
  1                          Spleen                                                        O146:H21        1.3
  1                          Lungs                                                         O6:H4           1.3
  1                          Liver                                                         O121:H7         1.3

E. coli=Escherichia coli

Phenotypically, the recovered *E. coli* strains were tested for their antimicrobial resistance against 15 antimicrobial agents ([Table-3](#T3){ref-type="table"}). Resistance was most frequently detected against penicillin (100%) followed by amoxicillin (94.5%), cefepime (95.8%), cefoxitin (90.4%), cefotaxime (76.7%), neomycin (89%), sulfamethoxazole (90.4%), streptomycin (73.9%), doxycycline (69.8%), tetracycline (53.4%), nalidixic acid (49.3%), ampicillin/sulbactam (46.5%), levofloxacin (42.4%), and to lesser extents chloramphenicol (30%), and norfloxacin (36.9%). All *E. coli* isolates displayed a MDR to antimicrobial agents ([Table-4](#T4){ref-type="table"}).

###### 

Antibiograms of isolated *E. coli* strains.

  Antimicrobial class    Antimicrobial agent   *E. coli* n=73 (%)
  ---------------------- --------------------- --------------------
  β-lactams              Amoxicillin           69 (94.5)
  Ampicillin/sulbactam   34 (46.5)             
  Penicillin             73 (100)              
  Cephalosporins         Cefepime              70 (95.8)
  Cefoxitin              66 (90.4)             
  Cefotaxime             56 (76.7)             
  Sulfonamides           Sulfamethoxazole      66 (90.4)
  Aminoglycosides        Neomycin              65 (89)
  Streptomycin           54 (73.9)             
  Tetracycline           Tetracycline          39 (53.4)
  Doxycycline            51 (69.8)             
  Phenicols              Chloramphenicol       22 (30)
  Quinolones             Levofloxacin          31 (42.4)
  Norfloxacin            27 (36.9)             
  Nalidixic acid         36 (49.3)             

E. coli=Escherichia coli

###### 

Antimicrobial resistance patterns and resistance genes profiles of *E. coli* strains.

  Number of strains   Strain antibiotic phenotypes                                    Resistance genes identified
  ------------------- --------------------------------------------------------------- -----------------------------------------------------
  3                   FEP, N, SMZ, NOR, NA, AX, P, CTX                                *bla*~TEM~, *aada*2, *sul*1
  4                   FEB, TE, N, S, DO, NA, AX, P, CTX                               *bla*~SHV~, *tetA* (A), *aad*A2
  1                   FEP, FOX, S, NA, AX, P, CTX                                     *bla*~SHV~
  2                   FEB, FOX, DO, NA, AX, S, SAM, P, CTX                            *bla*~TEM~, *tetA* (A)
  5                   FEP, TE, FOX, S, SMZ, DO, NA, AX, SAM, P, CTX                   bla~TEM~, *tetA* (A), sul1
  2                   FEB, TE, N, FOX, S, SMZ, DO, AX, P, CTX                         *tet*A (A), *sul*1
  6                   FEB, N, FOX, SMZ, DO, AX, P                                     *bla*~TEM~, *tetA* (A), *sul*1
  5                   FEB, N, FOX, SMZ, C, S, LEV, NOR, AX, SAM, P, CTX               *bla*~TEM~, *aada*2, *sul*1
  2                   FEB, TE, N, FOX, SMZ, DO, C, NA, AX, P                          *sul*1
  3                   FEP, N, FOX, S, SMZ, LEV, NOR, AX, SAM, P, CTX                  *bla*~SHV~, *bla*~TEM~, *tet*A (A), *aad*A2, *sul*1
  2                   FEB, TE, N, FOX, S, SMZ, DO, C, LEV, NOR, AX, P, CTX            *Tet*A (A), *sul*1
  5                   FEB, N, FOX, S, SMZ, NOR, AX, SAM, P, CTX                       *bla*~TEM~, *aada*2, *sul*1
  2                   FEB, TE, N, FOX, S, SMZ, DO, LEV, NA, SAM, AX, P, CTX           *bla*~SHV~, *tetA* (A)
  4                   FEB, N, FOX, S, SMZ, DO, LEV, NA, AX, P, CTX                    *bla*~TEM~, *aada*2, *sul*1
  4                   FEP, TE, N, FOX, SMZ, DO, AX, SAM, P, CTX                       *bla*~SHV~, *bla*TEM, *aada*2, *sul*1
  5                   FEB, TE, N, FOX, SMZ, DO, AX, P, CTX                            *bla*~TEM~, *tetA* (A) *aada*2, *sul*1
  3                   TE, N, FOX, S, SMZ, DO, C, NOR, NA, AX, SAM, P, CTX             *bla*~SHV,~ *tetA* (A), *aada*2, *sul*1
  5                   FEB, N, FOX, S, SMZ, LEV, AX, P                                 *bla*~TEM~, *sul*1
  6                   FEB, TE, N, FOX, S, SMZ, DO, C, LEV, NOR, NA, AX, SAM, P, CTX   *bla*~TEM~, *tetA* (A), *sul*1
  4                   FEB, TE, N, FOX, S, SMZ, DO, C, LEV, NA, SAM, P                 *bla*~TEM~, *tetA* (A), *aada*2, *sul*1

E. coli=Escherichia coli

Multiplex PCR was used for detection of antibiotic resistance genes including bla~TEM,~ bla~SHV,~ *aadA, tetA*, and *sul1* ([Figure-1](#F1){ref-type="fig"}). The recovery rate of these antibiotic resistance genes was 78%, 23%, 54%, 60%, and 87%, respectively. The *sul1* gene was the most prevalence gene (87%). In contrast, bla~SHV~ had the lowest prevalence (23%) as shown in [Table-4](#T4){ref-type="table"}.

![Agarose gel electrophoresis of multiplex PCR showing amplification of five antimicrobial resistance genes, *bla*~TEM~ at 516 bp, *sul*1 at 433 bp *aad*AA1 at 622 bp, *tetA* at 576 bp and *bla*~SHV~ at 392 bp, Lane L: DNA molecular size marker (1000 bp), Lane Neg: Negative control, Lane Pos: Positive control.](VetWorld-10-1167-g001){#F1}

Discussion {#sec1-4}
==========

*E. coli* is normally inhabitant the intestinal tract of poultry, but specific strains known as APEC have specific virulence factors and are able to cause avian colibacillosis. This disease is a major problem in poultry industry, as it causes high economic losses. Among 200 tested chicken samples, 73 (36.5%) *E. coli* isolates were recovered. These findings were nearly similar to the findings of Momtaz and Jamshidi \[[@ref17]\]. On the other hand, Kiliç *et al*. \[[@ref18]\] recorded a higher recovery rate (48%) of *E. coli* out a total of 100 examined chicken samples. In Egypt, 49 (20%) *E. coli* strains out of 242 samples were isolated \[[@ref19]\], which is relatively lower than our findings.

Serologically, APEC isolates usually belong to certain O serogroups, especially O1, O2, O8, O15, O18, O35, O78, O88, O109, and O115 \[[@ref20]\]. As first demonstrated by Sojka and Carnaghan \[[@ref21]\], O1, O2, and O78 are the most frequently isolated from colibacillosis in the many countries worldwide, that proven their role as particularly adapted pathogens that allow involvement in extraintestinal infections \[[@ref22]\]. In this study, twenty six O serogroups were identified among the 73 APEC isolates. Among the isolates that could be typed, the most prevalent serogroups were O78, O2 and O1 with a prevalence of 17.8%, 9.5%, and 9.5%, respectively. In many studies conducted in Egypt, nearly the same serotypes with a predominance of O78 have been identified \[[@ref12],[@ref23],[@ref24]\].

Antimicrobial agents are used in the prevention and treatment of infections and can also use as growth promoting agents in animals. Under the pressure of antibiotic selection, MDR bacteria have been aroused. In this study, *E. coli* showed a high rate of resistance to most antimicrobials tested. 100% of the tested *E. coli* isolates showed resistance against penicillin, 95.8% to cefepime and 94.5% to amoxicillin followed by considerable resistance to the rest of the examined agents. Most of these antimicrobials are regularly used as growth promoters or as prophylactic agents in the poultry industry in Egypt \[[@ref25],[@ref26]\] and concurred with the previous reports \[[@ref27]-[@ref32]\].

Many studies have been reported the presence of antibiotic resistance genes in APEC strains \[[@ref33]\]. The resistance genes mediated by plasmid can make the resistance prevail among various bacteria that lead to acquiring resistance genes without difficulty and produce MDR \[[@ref34],[@ref35]\].

Phenotypic multi-resistance of *E. coli* isolates to aminoglycoside, β-lactams, tetracycline, and sulfonamides antibiotics could be attributed to the presence of *aadA*, bla~TEM~*, tetA(A)*, and *sul1* resistance genes, respectively, among the tested isolates. Regarding the distribution of these antibiotic resistance genes among *E. coli* isolates, *sul*1 was detected in 64 (87%) isolates and bla~TEM~ identified in 57 (78%) isolates meanwhile *tetA* gene was identified in 44 (60%) isolates, 40 (54%) isolates were harbored *aadA*, and 17 (23.28%) isolates were carried bla~SHV~. These findings agree with Ammar *et al*. \[[@ref19]\] who found that bla~TEM~ and *sul*1 genes had the highest prevalence among the tested antibiotic resist genes which have being amplified in all tested isolates (100%). In addition, bla~TEM~ was detected in most of β-lactams resistance strains, similar results were reported by Ali \[[@ref36]\]. In contrast to our results, a relatively higher prevalence of bla~SHV~ was previously recorded in Spain (88%) \[[@ref13]\] and Egypt (79%) \[[@ref37]\]. These results are signifying that the results of antibiotic disc diffusion test actually agreed with the results of PCR for detection of the relevant antibiotic resistance genes.

The risk of spreading antibiotic resistance genes to humans should be considered when there is contamination of animal products, especially chickens, by bacterial strains resistant to most of antibiotics \[[@ref38]\]. Recently, many of extended-spectrum beta-lactamases (ESBL) producing *E. coli* have become a worldwide issue. The ESBL-positive *E. coli* strains are highly resistant to a wide range of antibiotics. Controlling such strains with usually used antibiotics is ineffective; recently, there are few antibacterial alternatives that remain effective against these MDR pathogens \[[@ref39]\].

Conclusion {#sec1-5}
==========

It is very important to control APEC because it represents a grave danger to poultry and is a potential source of transferring MDR genes to human-specific *E. coli* or other bacteria such as *Staphylococcus aureus* and *Shigella* strains. The fact that this pathogen is naturally present in daily consumed food should be considered as a serious public health and food biosafety.
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